Stem Cell Ophthalmology Treatment Study II (SCOTS2)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03011541 |
Recruitment Status :
Recruiting
First Posted : January 5, 2017
Last Update Posted : April 16, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Retinal Disease Age-Related Macular Degeneration Retinitis Pigmentosa Stargardt Disease Optic Neuropathy Nonarteritic Ischemic Optic Neuropathy Optic Atrophy Optic Nerve Disease Glaucoma Leber Hereditary Optic Neuropathy Blindness Vision Loss Night Vision Loss Partial Vision, Low Retinopathy Maculopathy Macular Degeneration Retina Atrophy | Procedure: Arm 1 | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 500 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Intervention Model Description: | Single Arm- Arm 1. Comparator is natural history of the disease. |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Bone Marrow Derived Stem Cell Ophthalmology Treatment Study II |
Actual Study Start Date : | January 2016 |
Estimated Primary Completion Date : | July 31, 2025 |
Estimated Study Completion Date : | July 31, 2026 |
Arm | Intervention/treatment |
---|---|
Arm 1
BMSC provided retrobulbar, subtenon and intravenous for one or both eyes
|
Procedure: Arm 1
Procedure/ Surgery: RB (Retrobulbar) Retrobulbar injection of Bone Marrow Derived Stem Cells (BMSC) Procedure/Surgery: ST (Subtenon) Subtenon injection of Bone Marrow Derived Stem Cells (BMSC) Procedure/Surgery: IV (Intravenous) Intravenous injection of Bone Marrow Derived Stem Cells (BMSC) Other Names:
|
- Visual Acuity [ Time Frame: Change from pre-procedure to 12 months ]Best corrected visual acuity will be measured with Snellen Eye Chart and the ETDRS (Early Treatment Diabetic Retinopathy Study)Eye Chart when available at each post- procedure visit. Intervals at minimum will be first post- procedure day,then 3 months, 6 months and 12 months post-procedure day. Recommended visit 1 month post -procedure day.
- Visual Fields [ Time Frame: Change from pre-procedure to 12 months ]Visual fields will be evaluated with automated perimetry during post- procedure visits as needed and specifically at 6 months and 12 months. Visual fields are a key measurement in patients with peripheral vision loss.
- Optical Coherence Tomography (OCT) [ Time Frame: Change from pre-procedure to 12 months ]OCT thickness of the retinal nerve fiber layer the optic nerve and/or macula during the post- procedure visits as needed and specifically at 6 and 12 months - if available.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Have objective, documented damage to the retina or optic nerve unlikely to improve OR
- Have objective, documented damage to the retina or optic nerve that is progressive AND have less than or equal to 20/30 best corrected central visual acuity in one or both eyes AND/OR an abnormal visual field in one or both eyes.
- Be at least 3 months post-surgical treatment intended to treat any ophthalmologic disease and stable.
- If under current medical therapy ( pharmacologic treatment) for a retinal or optic nerve disease be considered stable on that treatment and unlikely to have visual function improvement ( for example, glaucoma with intraocular pressure stable on topical medications but visual field damage ).
- Have the potential for improvement with BMSC treatment and be at minimal risk of any potential harm from the procedure.
- Be over the age of 18
- Be medically stable and able to be medically cleared by their primary care physician or a licensed primary care practitioner for the procedure.
- Medical clearance means that in the estimation of the primary care practitioner, the patient can reasonably be expected to undergo the procedure without significant medical risk to health.
Exclusion Criteria:
- Patients who are not capable of an adequate ophthalmologic examination or evaluation to document the pathology.
- Patients who are not capable or not willing to undergo follow up eye exams with the principle investigator or their ophthalmologist or optometrist as outlined in the protocol.
- Patients who are not capable of providing informed consent.
- Patients who may be at significant risk to general health or to the eyes and visual function should they undergo the procedure.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03011541
Contact: Steven Levy, MD | 203-423-9494 | stevenlevy@mdstemcells.com | |
Contact: Steven Levy, MD | 203-423-9494 |
United States, Connecticut | |
MD Stem Cells | Recruiting |
Westport, Connecticut, United States, 06880 | |
Contact: Steven Levy, MD 203-423-9494 stevenlevy@mdstemcells.com | |
Contact: Steven Levy, MD 203-423-9494 | |
Sub-Investigator: Steven Levy, MD | |
Principal Investigator: Jeffrey Weiss, MD | |
United States, Florida | |
MD Stem Cells | Recruiting |
Coral Springs, Florida, United States, 33065 | |
Contact: Steven Levy, MD 203-423-9494 | |
United Arab Emirates | |
Medcare Orthopaedics & Spine Hospital | Recruiting |
Dubai, United Arab Emirates | |
Contact: Steven Levy, MD (001) 2034239494 |
Study Chair: | Steven Levy, MD | MD Stem Cells | |
Principal Investigator: | Jeffrey Weiss, MD | Coral Springs |
Responsible Party: | MD Stem Cells |
ClinicalTrials.gov Identifier: | NCT03011541 |
Other Study ID Numbers: |
SCOTS2 |
First Posted: | January 5, 2017 Key Record Dates |
Last Update Posted: | April 16, 2024 |
Last Verified: | April 2024 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Plan Description: | The investigators do not plan to share individual participant data (IPD) |
Stargardt Disease Stem Cells Bone Marrow Derived Stem Cells BMSC Mesenchymal Stem Cells MSC Eye Disease Ophthalmology Ophthalmic Disease Retina Retinal Disease Macular Degeneration Age Related Macular Degeneration Myopic Macular Degeneration Geographic Atrophy |
Dry Macular Degeneration Wet Macular Degeneration Retinal Atrophy Retinal Dystrophy Hereditary Retinal Dystrophy Malattia Leventinese Retinitis Pigmentosa Cone Dystrophy Rod-Cone Dystrophy Cone-Rod Dystrophy Maculopathy Optic Nerve Disease Optic Atrophy Optic Neuropathy Ischemic Optic Neuropathy |
Stargardt Disease Peripheral Nervous System Diseases Optic Nerve Diseases Blindness Optic Neuropathy, Ischemic Optic Atrophy, Hereditary, Leber Nervous System Diseases Optic Atrophy Vision, Low Macular Degeneration Retinal Diseases Retinitis Retinitis Pigmentosa Atrophy Eye Diseases |
Neuromuscular Diseases Retinal Degeneration Pathological Conditions, Anatomical Eye Diseases, Hereditary Retinal Dystrophies Genetic Diseases, Inborn Cranial Nerve Diseases Vision Disorders Sensation Disorders Neurologic Manifestations Vascular Diseases Cardiovascular Diseases Optic Atrophies, Hereditary Heredodegenerative Disorders, Nervous System Neurodegenerative Diseases |